Regulatory Submissions, Information, and Document Management Forum

February 14-16
North Bethesda, MD

#RSIDM22
Electronic Submissions Update

Jonathan Resnick
Office of Business Informatics
Center for Drug Evaluation and Research
The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to DIA, its directors, officers, employees, volunteers, members, chapters, councils, Communities or affiliates, or any organization with which the presenter is employed or affiliated.

These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. DIA and the DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.
The views and opinions presented here represent those of the speaker and should not be considered to represent advice or guidance on behalf of the U.S. Food and Drug Administration.
Agenda

- eCTD Validations – *What’s new in 2022*
- eCTD v4.0 Update
- Benefits of eCTD
- Existing Challenges
eCTD Validations – *What’s new in 2022*
Starting March 1, 2022:

- **Module 1 using DTD 2.01 no longer supported**
  - Older version of eCTD M1, utilizing DTD 2.01, will no longer be supported
  - DTD 3.3 will be required to pass validation

- **eCTD validations 1306 and 1323 elevated to high severity errors**
  - FDA will begin rejecting submissions which fail eCTD validations 1306 and 1323
  - 1306: “No leaf element for file”
  - 1323: “No file for leaf element”
1306 & 1323 ErrorWarnings

CDER has been including a warning within the ESG 3rd Acknowledgement if 1306 or 1323 validation errors were found.

Starting March 1st, 2022 these errors will result in a rejection.
eCTD Validation 1306 Metrics

Time Period: 11/1/2021 – 12/31/2021

- 122 submissions (0.25% of total submissions processed)
- Average of 2 submissions per day

<table>
<thead>
<tr>
<th>Error</th>
<th>Description</th>
<th>Severity Level</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1306</td>
<td>You have submitted the file(s) listed in the validation report without corresponding reference in the backbone.</td>
<td>High</td>
<td>3/1/2022</td>
</tr>
</tbody>
</table>

**Error 1306 Trend**

**Number of 1306 Errors per Week**

**Error 1306 Breakdown by Application Type**

- IND 34%
- MF 29%
- ANDA 17%
- NDA 18%
- BLA 2%
Impacts from 1306 Errors

Submitted Files

Files not referenced in eCTD backbone and can't be easily identified or located by reviewers or FDA systems

eCTD Viewing Tool

Data Analytics Tools
eCTD Validation 1323

Time Period: 11/1/2021 – 12/31/2021

- 235 submissions (0.49% of total submissions processed)
- Average of 3-4 submissions per day

### Error 1323 Trend

<table>
<thead>
<tr>
<th>Error</th>
<th>Description</th>
<th>Severity Level</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1323</td>
<td>You have referenced the file(s) listed in the validation report from the us-regional.xml or index.xml files without providing the actual file(s).</td>
<td>High</td>
<td>3/1/2022</td>
</tr>
</tbody>
</table>

#### Error 1306 Breakdown by Application Type

<table>
<thead>
<tr>
<th>Application Type</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLA</td>
<td>41%</td>
</tr>
<tr>
<td>NDA</td>
<td>40%</td>
</tr>
<tr>
<td>IND</td>
<td>12%</td>
</tr>
<tr>
<td>MF</td>
<td>4%</td>
</tr>
<tr>
<td>ANDA</td>
<td>3%</td>
</tr>
</tbody>
</table>

Number of 1306 Errors per Week

[Chart showing error trend per week]
Impacts from 1323 Errors

eCTD Viewing Tool

- 1 Administrative Information and Prescribing Information
- 2 Common Technical Document Summaries
- 5 Clinical Study Reports
  - 5.2 Tabular Listing of all Clinical Studies
  - 5.2 Tabular List of Clinical Studies
  - 5.3 Clinical Study Reports
  - 5.3.5 Reports of Efficacy and Safety Studies
  - 5.3.5.1 Study Reports of Controlled Clinical Studies Per 8-Year Efficacy Study XYZ-123
  - 16.2.9 Other Safety
  - Study Report Body Chapter
  - 16. APPENDICES
  - Datasets
    - Analysis Datasets
    - Tabulation Datasets
    - Tabulation Datasets (SDTM)
      - define1-0-0
      - Define - XML
      - Define - PDF
      - Datasets
        - ADAE
        - ADCM
        - ADSL
        - AE
        - CE

Files appear to be in the submission but can’t be located by reviewers or FDA systems

eCTD Viewer Error:

- DocuBridge
- InfoBroker Error
  - Cannot get URL for passed Object ID
  - Show Details

OK
ICH eCTD v4.0 Materials

- ICH eCTD v4.0 Implementation Package v1.4

<table>
<thead>
<tr>
<th>Document</th>
<th>Version</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>Package History</td>
<td>1.4</td>
<td>PDF</td>
</tr>
<tr>
<td>eCTD v4.0 Implementation Guide</td>
<td>1.4</td>
<td>PDF</td>
</tr>
<tr>
<td>eCTD v4.0 Controlled Vocabularies</td>
<td>4.0</td>
<td>Spreadsheet</td>
</tr>
<tr>
<td>eCTD v3.2.2 Transition Mapping Message Controlled Vocabularies</td>
<td>3.0</td>
<td>Spreadsheet</td>
</tr>
<tr>
<td>Genericode Files</td>
<td>-</td>
<td>Folder and files</td>
</tr>
<tr>
<td>Schema Files</td>
<td>-</td>
<td>Folder and files</td>
</tr>
</tbody>
</table>

  - Implementation Package
  - Links to regional eCTD v4.0 webpages
  - Change Control – Submit questions and change requests

www.fda.gov
ICH eCTD v4.0 Materials

- **Support Documentation**
  - Explains the contents of the Implementation Package as an overview of the eCTD v4.0 implementation
  - Target audience is business and technical personnel
  - Updated in accordance with Implementation Guide updates

- **Orientation Material**
  - Provides an outline of eCTD v4.0 concept from business perspective
  - Target audience is business personnel and management
  - Updated in accordance with Implementation Guide updates
FDA Implementation Strategy

❖ Initial release/acceptance of new applications in eCTD v4.0
  – Allows for development of eCTD v4.0 applications across regions
  – FDA is working with its tool vendor to incorporate eCTD v4.0 functionality
    • Received/installed software update – December 2021
  – Perform testing in 2022 (testing has begun!)
  – Begin accepting new applications in eCTD v4.0 in 2023

❖ Future phases
  – Transition of current applications (existing 3.2.2 transitioning to 4.0)
  – Two-way communication
FDA eCTD v4.0 Update

- FDA Module 1 Implementation Package v1.4
  - USFDA Module 1 Electronic Common Technical Document (eCTD) v4.0 Implementation Guide v1.4
  - USFDA Module 1 Regional XML Samples

  - Implementation Package (June 2021)
  - Technical Conformance Guide (January 2021)
  - Validation Specifications (June 2021)
  - Comprehensive Table of Contents Headings and Hierarchy (June 2021)
  - Link to ICH eCTD v4.0 webpage
eCTD v4.0 Enhancements

- Complete standard
  - Regional model/xml
  - Simplified submission management

- Message is managed through controlled vocabularies

- Enhanced control of dossier
  - Document Reuse, Document Ordering, Keyword/Attribute Mods, Lifecycle, Group Title

- Enhanced identification of information contained within a submission
  - Document metadata level
Benefits of eCTD
Electronic Submissions to CDER

- In 2021, CDER received 91% of submissions in eCTD format
- Most non-eCTD submissions were Research INDs
FDA Tools & Systems to Support Reviews

- eCTD formatted submissions support reviewers to locate and view submission content in context

### eCTD Viewing

- 1 Administrative Information and Prescribing Information
- 2 Common Technical Document Summaries
- 5 Clinical Study Reports
  - 5.2 Tabular Listing of all Clinical Studies
  - 5.2 Tabular List of Clinical Studies
- 5.3 Clinical Study Reports
  - 5.3.5 Reports of Efficacy and Safety Studies
  - 5.3.5.1 Study Reports of Controlled Clinical Studies Per M300-L102 8-year Efficacy
- 15.2.9 Other Safety
- Study Report Body Chapter
- 16. APPENDICES
- Datasets
  - Analysis Datasets
  - Tabulation Datasets
    - Tabulation Datasets (SDTM)
      - define1-0-0
      - Define - XML
      - Define - PDF
  - Datasets
    - ADAE
    - ADCM
    - ADSL
    - AE
    - CE

### Advanced Search & Filtering

- History of application and submission content
- Searching across applications
- Searching information within documents
- Searching trials based on key attributes across applications and studies
- Searching information linked to external data sources
- Aggregating similar application and study information

Advanced tools and capabilities improves efficiency and consistency of review decisions

www.fda.gov
Benefits of eCTD

Electronic Submissions Gateway

Sponsor Submission

Faster, more efficient reviews and communications

Regulatory Review

Data & Metadata Leveraged to Automate Workflows & Notifications

Reviewers

Structured Submission Content Stored

eCTD Sequence

- Index.xml
- us-regional.xml
- Regulatory forms (356h, 1571)

M1

- stf.xml
- define.xml

M2-M5

Extract & Store Submission Data & Metadata

Suite of Review Tools

Advanced review capabilities to search, filter, automate analyses

www.fda.gov
Existing Challenges and Path Forward
Challenge in 1990s/Early 2000s

Transform Drug Applications from paper to electronic

Electronic submissions follow the ICH Electronic Common Technical Document Standard (eCTD)
  • eCTD submissions contain a standardized message
    • Structured data is used to identify key information for each file in the submission
      • Document Name, File Path, Life Cycle, Standardized Heading Placement, Study it belongs to, and more..
Today’s Challenge

Many files contained within an eCTD submission do not conform to a data standard. Some submissions (i.e. Research IND) are not in eCTD. The more files we can transition from “paper on glass” to structured data, the more dynamic the analytic tools can be for review workflow and data analysis.
Solving Today’s Challenge

FDA is focusing on applying data standards and structured content to more documents within submissions

- CDER NextGen Portal - Application Builder for Research IND
- Revisiting content and structure in FDA Fillable Forms
- Specify data format/standard for files submitted in Module 3
- Continue focus on Study Data in Standardized Format
Stay Informed! Starting March 1, 2022 the following mistakes will result in rejection:
- Using FDA’s old version of Module 1 (DTD v2.01)
- Triggering eCTD validation error 1306 or 1323

ECTD v4 is coming
- Voluntary submission planned for 2023
- FDA webpage dedicated to eCTD v4 to obtain guides, specifications, and more

Benefits of eCTD
- Standardized view and elements are used in downstream tools for analytics and reviewer workflow
- Analytical tools developed can leverage quality data to perform advanced data analysis in supporting regulatory review operations

Challenges and Path Forward
- While eCTD has successfully standardized the format a submission and CDISC has helped to standardize studies, these submissions still contain many non-standardized PDF documents ("paper on glass")
  - CDER has projects under way such as PQ/CMC to address
- Many Research INDs come in non-eCTD (one or few PDF documents)
  - CDER developed an "application builder" for Research INDs in the CDER NextGen Portal to collect key structured data to associate with individual files a sponsor uploads
Thank You

Resources:

- FDA eCTD Website: [https://www.fda.gov/ectd](https://www.fda.gov/ectd)
- FDA CDER eSub Team: esub@fda.hhs.gov
- FDA CDER eData Team: edata@fda.hhs.gov